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Objective: Docosahexaenoic acid (DHA, 22:6, n-3) is a major structural component of neural
tissue critical to neurotransmission and mood regulation. Poor maternal dietary intake
coupled with accelerated maternal-fetal transfer of DHA compound risk for maternal
deficiency. The objective of this investigation was to determine if maternal DHA supple-
mentation is efficacious in reducing symptoms of postpartum depression.
Methods: This pilot investigation was a randomized, double-blinded, placebo controlled
investigation of the role of DHA in preventing risk for postpartum depression. Women were
assigned to: i) Placebo (no DHA, corn oil capsule), ii) DHA (300 mg DHA, fish oil capsule).
Capsules were consumed from 24 to 40 weeks gestation (1 capsule 5 days/week). Forty-two
participants were recruited (n ¼ 20, intervention; n ¼ 22, placebo). Maternal DHA status and
depressive symptoms were followed from 24 to 40 weeks gestation using the Center for
Epidemiologic Studies Depression Scale (CES-D) and the Postpartum Depression Screening
Scale (PDSS) from 2 weeks to 6 months postpartum.
Results: PDSS total scores were significantly lower (p ¼ 0.016; 46.03 ± 2.17, intervention vs.
52.11 ± 2.4, placebo) in the intervention group with less anxiety/insecurity (p ¼ 0.03),
emotional lability (p ¼ 0.04) and loss of self (p ¼ 0.02).
Conclusions: Women in the DHA intervention group had fewer symptoms of postpartum
depression compared to the placebo group. These results support the notion that the
consumption of DHA by pregnant women can be efficacious in preventing depressive
symptoms and highlight a need for further larger-scale investigations using the PDSS in
tandem with a diagnostic evaluation.
Copyright © 2014, Chinese Nursing Association. Production and hosting by Elsevier
(Singapore) Pte Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/3.0/).n.edu (M.P. Judge), Cheryl.Beck@uconn.edu (C.T. Beck), holiday.durham@pbrc.edu (H.
M. McKelvey), clammi-keefe@agcenter.lsu.edu (C.J. Lammi-Keefe).
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childbirth, is a major public health problem [1], affecting
13e15% of pregnant women in the U.S. [2]. Further, 25e50% of
women diagnosed with postpartum depression have episodic
events for up to six months ormore [3]. Postpartum depression
is a universal phenomenon, affecting women in countries
throughout the world [4] and suffered covertly [5]. Because
postpartum depression is a term applied to a wide range of
postpartum emotional disorders, women may be mis-
diagnosed. Current DSM-IV-TR guidelines [6] outline that, in
addition to depressed mood or loss of interest or pleasure in
activities, women need to have three or more other symptoms
including insomnia, psychomotor agitation or retardation, fa-
tigue, feelings of worthlessness or excessive or inappropriate
guilt, inability to concentrate, or suicidal thoughts. The
importance of preventing, diagnosing, and treating postpartum
depression is underscored by the findings that postpartum
depression has significant adverse effects on children's cogni-
tive and emotional development [7,8]. The evidence for a
demonstrated benefit of fish/seafood and n-3 long chain fatty
acids (n-3 LCPUFAs) in preventing or decreasing symptom-
atology of postpartum depression is mixed [9e12]. Given the
teratogenic effects of some medications traditionally used to
treat depressive disorders, there is the need to explore possible
alternative treatments or augmentation to traditional medical
treatments for women with depression associated with preg-
nancy. N-3 LCPUFAs present a possible treatment or adjuvant
to treatment for this disorder.
Given the collective evidence we report, the major hy-
pothesis for this investigationwas:Womenwho consume fish
oil during pregnancy will have lower postpartum depressive
symptomatology measured using the PDSS (total score and
individual symptomdomains) compared to the placebo group.
In the current study we employed the Postpartum Depression
Screening Scale (PDSS) to evaluate if pregnant women who
consumed fish oil capsules had decreased postpartum
depressive symptoms compared to women consuming a
placebo.Fig. 1 e Schedule of intervention & sampling. 24 h recall: 24 h d
Depression Scale; Blood (1e3): Fasting maternal blood draw; Ca2.1. Research design
This pilot investigation was a double-blind, randomized,
control trial, with repeated measures of the primary investi-
gative outcome of maternal postpartum depressive symp-
tomatology at 2 and 6 weeks, and 3 and 6months postpartum.
All participants consumed one capsule (intervention: fish oil
with 300 mg docosahexaenoic acid [DHA, 22:6, n-3] per
capsule; placebo: corn oil) 5 days weekly. Participants were
assigned randomly to either intervention (n ¼ 20) or placebo
(n¼ 22), and consumed capsules from 24weeks gestation until
delivery. All study procedures were approved by the Univer-
sity of Connecticut and Louisiana State University and in
accordance with the Code of Ethics of the World Medical
Association.2.2. Sample/setting
Forty-twomaternal-infant dyads completed the investigation.
Inclusion criteria were: No other births in the previous two
years; 20 weeks pregnant; and 18e35 years of age. Women
with a self-reported significant medical history were excluded
(i.e., currently being treated for depression/psychiatric illness,
addiction problems, hyperlipidemia, hypertension, renal dis-
ease, liver disease, or diabetes). Recruitment of participants
was conducted in collaboration with several Women Infants
and Children (WIC) offices and hospitals in New England.
Determination of sample size for a full-scale investigation
was based upon a previous investigation comparing rates of
postpartum depression with respect to seafood consumption
[9]. The sample in this pilot investigation (n ¼ 42) is 78% of the
minimum calculated to be necessary for a full-scale investi-
gation (effect size based upon a power of 0.8, significance level
of 0.05).
All participants were randomized utilizing a coded marble
system and assigned to groups by a trained individual who
was not a research team member. Packages containing cap-
sules were labeled identically and listed only sequential studyietary recall; CES-D: Center for Epidemiologic Studies
psule log; PDSS: Postpartum Depression Screening Scale.
Fig. 2 e CONSORT diagram of trial flow.
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with group assignments was maintained in a secure location
away from the researchers to ensure adequate blinding
throughout the investigation from recruitment to the
completion of data analysis. Identical numbered packages
were assembled in advance for use by the research team in
enrolling participants. Participants were blinded to group
allocation through identical dose and packaging. To monitor
protocol compliance, women kept logs of capsule intake
(Fig. 1).2.3. Measures
2.3.1. Blood collection/fatty acid analyses
Maternal venous blood samples (Fig. 1) were collected into
ethylenediaminetetraacetic acid (EDTA)-containing tubes.
Maternal RBC fatty acids were determined using methodolo-
gies previously reported [13].
2.3.2. Prenatal/postnatal assessment of maternal depressive
symptoms
The Center for Epidemiologic Studies Depression Scale (CES-
D) [14] is a self-report sensitive to emotional state and
depressive symptoms in the general population and contains
20 items with a 4 point Likert response: 1 ¼ rarely, 2 ¼ 1e2
days, 3 ¼ 3e4 days, or 4 ¼ 5e7 days in the assessment week
(score range 0e60). The CES-D has a test-retest reliability of
r ¼ 0.51e0.67 and a Cronbach's a of 0.85e0.9 and 64% sensi-
tivity and 94% specificity with a positive predictive value of
33% [15]. The CES-D was administered at baseline and again
prior to delivery (Fig. 1).
To evaluate the primary study outcome, postpartum
depressive symptomatology, the PDSS [16] was administered
four times postpartum: at 2 weeks, 6 weeks, andmonths 3 and
6 (Fig. 1). The PDSS is a self-report scale consisting of 35 items
designed to reflect symptoms over the previous 2-weeks. The
response options range from 1 ¼ strongly disagree to
5 ¼ strongly agree (score range 35e175). It consists of seven
symptom content scales: Sleeping/Eating Disturbances, Loss
of Self, Anxiety/Insecurity, Guilt/Shame, Emotional Lability,Mental Confusion, and Suicidal Thoughts, with high reliability
(a¼ 0.97) for the total scale and coefficients ranging from .83 to
.94 for the seven symptom subscales [16]. Scores 80 indicate
a positive screen for postpartum depression and need for a
referral for a formal diagnostic evaluation by a trained mental
health provider using a Structured Clinical Interview for DSM-
IV Axis 1 Disorders (SCID) [17]. Beck and Gable [16] reported
the PDSS had sensitivity of 94% and specificity of 98% when
validated with clinical diagnosis. Mothers diagnosed with
postpartum depression during the intervention were referred
for follow-up and treatment. Participants with high scores on
the suicidal ideation domain were referred immediately to
emergency room psychiatric services. To assess consistency
in participant response to PDSS items, the PDSS inconsistent
responding (INC) index was used, and scores of 4e6 indicate
an 85% e 97% (respectively) likelihood of inconsistency [16].2.4. Statistical analyses
Statistical analyses for main effects were conducted using the
Statistical Analysis System (SAS) [18] software. Analyses of
baseline characteristics included the Student t-test for
numeric and chi-square tests for categorical variables. The
PROC MIXED procedure was used to evaluate the primary
outcome measure of change over time among all four of the
PDSS assessments and for individual domain scores.3. Results
Fig. 2 provides the CONSORT diagram outlining the flow of
participants from initial contact to final analysis.
The total CES-D score in this investigation had an a
coefficient ¼ 0.89 (intervention ¼ 0.90; placebo ¼ 0.90). There
were no significant group differences between CES-D scores at
baseline, p¼ 0.97 (intervention 14.2 ± 9.5; placebo 14.1± 10.7) or
at 30e32 wks gestation, p ¼ 0.24 (intervention 12.6 ± 8.3; pla-
cebo 9.5 ± 8.3). For the total PDSS in this investigation the
combined groups had an a coefficient ¼ 0.94 (intervention ¼ 0
.93; placebo ¼ 0.94). The mean PDSS INC score for our placebo
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(a coefficient ¼ 0.71 for the entire cohort; intervention ¼ 0 .58;
placebo ¼ 0.82), which indicated that the PDSS was completed
consistently by the sample. There were no significant group
differences for any of the baseline characteristics (i.e. age, pre-
pregnancy weight, number of live births, income, education,
ethnicity, number of people in the household, history of
depression, or previous treatment for depression).
The statistical model controlled for maternal CES-D score
prior to delivery and PDSS INC index score as they were
significantly related to PDSS scores. Additionally, age, dietary
DHA outside of intervention, and ethnicity were included as
covariates due to evidence that they operate as confounders of
the group effect. Using this model, there was a significant
group effect (p ¼ 0.016), with lower mean PDSS scores in the
intervention group across all 4 times evaluating the collective
group difference across all time points using the PROC MIXED
procedure for repeated measures analysis over time [LS Mean
(SEM)]: intervention, 46.03 (2.17); placebo, 52.11 (2.4), Table 1.
Women in the intervention group had PDSS scores 6 points
lower overall compared to the placebo group (Table 1). Fig. 3
outlines the least square (LS) mean PDSS scores at the 4 in-
dividual time-points. Individual LS means were compared
individually between groups at 2 weeks and the intervention
group PDSS LS mean score was significantly lower compared
to the placebo group (p ¼ 0.0124). In the entire cohort, 9.5% of
participants had a PDSS score 80 (1 participant in interven-
tion group, 3 in placebo group).
Using this model, individual domains (Sleeping/Eating
Disturbances, Loss of Self, Anxiety/Insecurity, Guilt/Shame,
Emotional Lability, Mental Confusion, and Suicidal Thoughts)
of the PDSS were compared (Table 1). Anxiety/insecurity,
emotional lability, mental confusion, and loss of self were
significantly lower in theDHA intervention group compared to
the placebo group across the 4 time points (Table 1). RBC DHA
(weight%) was significantly higher in the DHA intervention
group at 20e22 weeks (p < 0.01, DHA ¼ 3.62% (0.83);
placebo ¼ 3.0% (0.63)) and 6 weeks postpartum (p ¼ 0.001,







PDSS total score Int. 47.65 (12.96) 47.61 (14.31) 45.28
Placebo 53.86 (15.25) 47.40 (12.42) 42.63
Disturbances sleep/eating Int. 8.05 (3.68) 7.39 (4.02) 7.72
Placebo 8.77 (3.31) 7.65 (2.89) 6.22
Anxiety/insecurity Int. 8.30 (3.56) 7.72 (3.18) 7.00
Placebo 9.45 (3.54) 7.85 (3.00) 6.56
Emotional lability Int. 7.35 (2.18) 8.22 (3.62) 7.06
Placebo 8.86 (3.54) 7.65 (2.32) 6.89
Mental confusion Int. 6.90 (2.77) 7.61 (4.06) 6.89
Placebo 8.23 (3.64) 7.20 (2.84) 6.39
Loss of self Int. 6.20 (1.96) 5.67 (1.24) 5.72
Placebo 7.00 (2.37) 6.10 (1.74) 5.78
Guilt Int. 5.75 (1.12) 5.83 (1.42) 5.89
Placebo 6.41 (1.47) 5.95 (1.76) 5.39
Suicide Int. 5.10 (0.31) 5.17 (0.71) 5.00
Placebo 5.14 (0.47) 5.10 (0.31) 5.00
a ¼ significant group difference. NS ¼ not significant.4. Discussion and conclusion
Lower total PDSS scores in the intervention group compared
to the placebo group point to benefit in reducing symptoms of
postpartum depression in women consuming supplemental
DHA during pregnancy. The clinically and significantly lower
mean PDSS score obtained closest to the intervention period,
at 2 weeks postpartum in the DHA supplemented group, point
to a particular benefit during the early postpartum period. The
maternal CES-D score during pregnancy was a significant
predictor of elevated postpartum depressive symptoms. This
finding highlights the idea that depressed maternal mood
during pregnancy is likely to result in more symptoms of
depression postpartum. This finding also supports earlier
research identifying psychological disturbance during the
prenatal period as a significant predictor of postpartum
depression [19,20]. Additionally, our finding has clinical im-
plications for routine screening for depression during preg-
nancy to facilitate early intervention. Higher inconsistency in
responding (i.e., INC score) to like PDSS questions was asso-
ciated with more postpartum depressive symptoms. Mental
confusion and emotional lability are associated with post-
partum depression and are likely to interfere with consistency
in responding [16]. The reported 6-point reduction in PDSS
total score underlines that individuals who are either at risk
for or actually have elevated symptoms of postpartum
depression may experience a moderate benefit, thus high-
lighting the need for larger-scale investigations. These data
demonstrate that women consuming DHA during pregnancy
had less maternal anxiety/insecurity, emotional lability and
loss of self, compared to the placebo group. Collectively, lower
scores in these domains may contribute significantly to
maternal feeling of wellness and quality of life during the
postpartum period.
Underlying mechanisms to explain depressed mood
related to DHA deficiency have been explored. Research in
animal models has linked DHA deficiency to alterations in








(12.25) 45.55 (13.50) a46.03 (2.17) P ¼ 0.016
(9.52) 48.42 (17.18) a52.11 (2.4)
(3.68) 6.80 (3.44) 8.1 (0.6) NS
(1.83) 7.00 (2.67) 9.1 (0.6)
(2.28) 7.65 (3.70) a7.7 (0.6) P ¼ 0.03
(2.38) 8.11 (3.51) a9.0 (0.6)
(2.44) 7.20 (3.21) a7.01 (0.6) P ¼ 0.04
(2.45) 8.16 (4.54) a8.3 (0.7)
(2.91) 7.55 (3.15) 7.1 (0.57) NS
(2.35) 7.68 (3.53) 8.4 (0.6)
(1.32) 5.45 (1.00) a5.5 (0.3) P ¼ 0.02
(1.56) 6.42 (2.71) a6.4 (0.35)
(1.94) 5.95 (1.57) 5.4 (0.3) NS
(0.85) 5.74 (1.37) 5.7 (0.3)
(0.00) 4.95 (0.22) 5.13 (0.1) NS
(0.00) 5.47 (1.43) 5.2 (0.1)
Fig. 3 e PDSS LS mean scores by group at individual time points. ( ) ¼ Standard Deviation.
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that dietary n-3 fatty acids shift endocannabinoids in the
brain and that increased dietary DHA results in increased
brain and circulating DHA-endocannabinoid species. These
impacts of DHA on mood regulation provide a basis for the
higher PDSS scores and variability observed in the placebo
group with better mood stability and lower PDSS scores in the
intervention group.
In the current study the intervention group had higher RBC
DHA relative wt% compared to the placebo group. At baseline
and in the postpartum period RBC DHA wt% was significantly
higher in the intervention group compared to the placebo
group without a significant time effect. Our finding of no time
effect on a biochemical marker for a moderate supplementa-
tion with DHA in women during pregnancy has previously
been discussed [13].
Limitations of this pilot investigation include that the
majority of the participants recruited were of low socio-
economic status thus limiting generalizability to the general
population. Attrition in this investigation was attributed pre-
dominately to associated lifestyle and population character-
istics. No adverse maternal or infant outcomes were reported
associated with this investigation.In summary, our findings support the efficacy of DHA in
decreasing postpartum depressive symptomatology, and
these results highlight a need for further larger-scale in-
vestigations. Fewer total depressive symptoms, less anxiety/
insecurity, less emotional lability and a better sense of self
have implications for bothmaternal and infantwell-being and
quality of life. Mothers with depressive symptoms are more
likely to discontinue breastfeeding [23], display withdrawn or
intrusive interaction patterns [24], be less responsive to in-
fants, report more negative emotions relating to care for their
infants [25], and be less likely to engage in enrichment activ-
ities such as reading, singing and telling stories to infants [26].
Negative mothereinfant interactions lead to problematic in-
fant developmental patterns [27]. This interruption in moth-
ereinfant interaction negatively impacts toddlers' attachment
as well as self-esteem and independence [28]. Our finding of-
fers a contribution toward efforts to increase awareness of the
need for further larger-scale investigations focused on DHA in
maternal mental health for the general population and as an
intervention for high-risk groups. Although our lower post-
partum depressive symptomatology with DHA intervention is
in contrast to the findings of others [11,29], the use of the
Edinburgh Postnatal Depression Scale [30] in those studies
i n t e r n a t i o n a l j o u rn a l o f n u r s i n g s c i e n c e s 1 ( 2 0 1 4 ) 3 3 9e3 4 5344compared to PDSS [16] with its specificity for postpartum
symptomatology may be a possible underlying explanation
for the dichotomy, and this should be further explored. While
our sample was limited in size, our evidence points also to a
need for more careful consideration of instrumentation used
in the assessment of postpartum depressive symptoms in
future investigations.Author contributions
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